These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Thirty-five years in the progress of hairy cell leukemia. Bouroncle BA Leuk Lymphoma; 1994; 14 Suppl 1():1-12. PubMed ID: 7820038 [TBL] [Abstract][Full Text] [Related]
67. Natural killer cell function and malignant cell phenotype in hairy cell leukaemia. Ogmundsdóttir HM; Thorsteinsson L; Sigfússon A; Sveinsdóttir S; Björnsson S; Eyjólfsson G; Jóhannesson GM; Jensson O APMIS; 1992 Jan; 100(1):10-20. PubMed ID: 1536717 [TBL] [Abstract][Full Text] [Related]
69. Sustained long-term remissions with weekly interferon maintenance therapy in hairy cell leukemia. Ramakrishna R; Manoharan A Asia Pac J Clin Oncol; 2010 Sep; 6(3):210-2. PubMed ID: 20887503 [TBL] [Abstract][Full Text] [Related]
70. Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Schmid M; Porzsolt F Leuk Lymphoma; 1995 May; 17(5-6):401-10. PubMed ID: 7549830 [TBL] [Abstract][Full Text] [Related]
71. Bone-marrow biopsy in hairy cell leukaemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapies. Pileri S; Sabattini E; Poggi S; Merla E; Raspadori D; Benfenati D; Rondelli D; Benni M; Ventura MA; Falini B Leuk Lymphoma; 1994; 14 Suppl 1():67-71. PubMed ID: 7820056 [TBL] [Abstract][Full Text] [Related]
72. Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Pawson R; A'Hern R; Catovsky D Leuk Lymphoma; 1996 Jun; 22(1-2):103-6. PubMed ID: 8724535 [TBL] [Abstract][Full Text] [Related]
73. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells. Billard C; Sigaux F; Castaigne S; Valensi F; Flandrin G; Degos L; Falcoff E; Aguet M Blood; 1986 Mar; 67(3):821-6. PubMed ID: 2936410 [TBL] [Abstract][Full Text] [Related]
74. RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells. Chaigne-Delalande B; Deuve L; Reuzeau E; Basoni C; Lafarge D; Varon C; Tatin F; Anies G; Garand R; Kramer I; Génot E Am J Pathol; 2006 Feb; 168(2):562-73. PubMed ID: 16436670 [TBL] [Abstract][Full Text] [Related]
75. Hairy cell leukemia: clinical features and therapeutic advances. Lembersky BC; Golomb HM Cancer Metastasis Rev; 1987; 6(3):283-300. PubMed ID: 2446791 [TBL] [Abstract][Full Text] [Related]
77. Relationship between immunological phenotype and hematological response to alpha-IFN treatment in 35 patients with hairy cell leukemia. Lauria F; Zinzani PL; Raspadori D; Foà R; Buzzi M; Gugliotta L; Bocchia M; Benfenati D; Tura S Eur J Haematol Suppl; 1990; 52():3-6. PubMed ID: 2279543 [TBL] [Abstract][Full Text] [Related]
78. Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Heslop HE; Brenner MK; Ganeshaguru K; Hoffbrand AV Br J Haematol; 1991 Oct; 79 Suppl 1():14-6. PubMed ID: 1931702 [TBL] [Abstract][Full Text] [Related]
79. Characterization of a new cell line (ESKOL) resembling hairy-cell leukemia: a model for oncogene regulation and late B-cell differentiation. Harvey W; Srour EF; Turner R; Carey R; Maze R; Starrett B; Kanagala R; Pereira D; Merchant P; Taylor M Leuk Res; 1991; 15(8):733-44. PubMed ID: 1895754 [TBL] [Abstract][Full Text] [Related]